Bright Minds is Unaware of Any Material Changes | Psychedelic Invest

NEW YORK, Sept. 12, 2024 /CNW/ – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with…

Myricx Bio signs licence deal for WuXi Biologics’ antibody

Share this article Myricx plans to conduct preclinical as well as clinical development of the newly developed ADC for solid tumours. Credit: Gorodenkoff / Shutterstock.com.

November 22, 2023

Osteoarthritis linked to accelerated progression of severe long-term conditions

Osteoarthritis-;a condition in which the protective cartilage on the ends of bones breaks down-;may more than double the risk of speedy progression to accumulating severe

July 10, 2024

Hemodiafiltration Reduced Dialysis Mortality in Kidney Failure

High-dose hemodiafiltration improved survival compared with standard hemodialysis for patients with kidney failure resulting in the need for kidney-replacement therapy, according to the randomized CONVINCE

June 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.